Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of <italic style="font-style: italic">EGFR</italic>-mutated advanced NSCLC

LIU Ran; GAO Shengnan; ZHANG Yuxi; ZHANG Ranran; LI Congxin; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2026.05.14

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC

更新时间：2026-03-10

- Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC
- ZHONGGUO YAOFANG Vol. 37, Issue 5, Pages: 633-638(2026)
- 作者机构：
  
  1.河北医科大学第三医院药学部，石家庄　050051
  2.河北医科大学研究生学院，石家庄　050017
  3.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.05.14
  CLC： R956;R979.1
- Received：22 October 2025，
  
  Revised：2026-03-02，
  
  Accepted：02 March 2026，
  
  Published：15 March 2026
- 稿件说明：
移动端阅览
刘冉,高胜男,张羽曦,等.埃万妥单抗联合兰泽替尼一线治疗EGFR突变晚期NSCLC的成本-效用分析 ^Δ[J].中国药房,2026,37(05):633-638.

LIU Ran,GAO Shengnan,ZHANG Yuxi,et al.Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC[J].ZHONGGUO YAOFANG,2026,37(05):633-638.
刘冉,高胜男,张羽曦,等.埃万妥单抗联合兰泽替尼一线治疗EGFR突变晚期NSCLC的成本-效用分析 ^Δ[J].中国药房,2026,37(05):633-638. DOI： 10.6039/j.issn.1001-0408.2026.05.14.

LIU Ran,GAO Shengnan,ZHANG Yuxi,et al.Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC[J].ZHONGGUO YAOFANG,2026,37(05):633-638. DOI： 10.6039/j.issn.1001-0408.2026.05.14.

摘要

目的

从我国卫生体系角度出发，评价埃万妥单抗联合兰泽替尼（以下简称“AL”）方案一线治疗

EGFR

突变晚期非小细胞肺癌（NSCLC）的经济性。

方法

根据MARIPOSA研究最新数据构建分区生存模型，模拟时限设置为10年，循环周期为28 d，以质量调整生命年（QALY）为主要输出指标，以3倍2024年我国人均国内生产总值为意愿支付（WTP）阈值（287 247元/QALY），采用成本-效用分析法，计算AL相对于奥希替尼单药方案一线治疗

EGFR

突变晚期NSCLC的增量成本-效果比（ICER）；采用单因素敏感性分析和概率敏感性分析评估模型的稳健性；采用情境分析评估不同健康状态效用值对结果的影响，并确定AL方案具有经济性时埃万妥单抗和兰泽替尼的降价幅度。

结果

相对于奥希替尼单药方案，AL方案一线治疗

EGFR

突变晚期NSCLC的ICER为2 062 096.15元/QALY，远高于本研究设定的WTP阈值。单因素敏感性分析结果显示，无进展生存状态效用值和埃万妥单抗价格是影响ICER的主要因素。概率敏感性分析结果显示，当WTP阈值为2 050 000元/QALY时，AL方案才开始具有经济性。情境分析结果显示，改变效用值，AL方案依然不具有经济性；当埃万妥单抗（350 mg）价格分别下降80%、85%、90%时，兰泽替尼（80 mg）需分别降价95.97%、40.63%、5.29%，才能让AL方案的ICER稳定落在上述WTP阈值内。

结论

在本研究设定的WTP阈值下，相对于奥希替尼单药方案，AL方案一线治疗

EGFR

突变晚期NSCLC不具有经济性；联合药物需要同时大幅降价，才能减轻患者的用药负担。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of amivantamab combined with lazertinib （hereinafter referred to as “AL”） regimen as first-line treatment for

EGFR

-mutated advanced non-small cell lung cancer （NSCLC） from the perspective of China’s healthcare system.

METHODS

A partitioned survival model was established based on updated data from the MARIPOSA study， with a 10-year time horizon and 28-day cycles. The primary outcome index was quality adjusted life year （QALY）， and the willingness-to-pay （WTP） threshold was set at three times China’s per capita GDP in 2024 （287 247 yuan/QALY）. Cost-utility analysis was used to calculate the incremental cost-effectiveness ratio （ICER） of AL regimen versus osimertinib monotherapy regimen as first-line treatment for

EGFR

-mutated advanced NSCLC. One-way and probabilistic sensitivity analyses were performed to test model robustness. Scena

rio analyses were conducted to explore the impact of utility values for different health states on the outcomes and determine the required price reductions of amivantamab and lazertinib to achieve cost-effectiveness.

RESULTS

Compared with the osimertinib monotherapy regimen， the ICER for the AL regimen as first-line treatment for advanced

EGFR

-mutated NSCLC was 2 062 096.15 yuan/QALY， significantly exceeding the WTP threshold established in this study. One-way sensitivity analysis revealed that the utility value of progression-free survival state and the price of amivantamab were the primary factors influencing the ICER. Probabilistic sensitivity analysis revealed that the AL regimen only became cost-effective when the WTP threshold was set at 2 050 000 yuan/QALY. Scenario analysis indicated that altering the utility value still rendered the AL regimen non-cost-effective. When amivantamab （350 mg） prices decreased by 80%， 85%， and 90% respectively， lazertinib （80 mg） prices would need to decrease by 95.97%， 40.63%， 5.29%， respectively. This would enable the AL regimen’s ICER to consistently fall within the WTP threshold established in this study.

CONCLUSIONS

At the WTP threshold established in this study， the AL regimen does not demonstrate cost-effectiveness for first-line treatment of advanced

EGFR

-mutated NSCLC compared to the osimertinib monotherapy regimen. Significant price reductions for both drugs would be required to alleviate the financial burden on patients.

关键词

Keywords

references

GUO L W ， ZHU C X ， CAI L ， et al . Global burden of lung cancer in 2022 and projected burden in 2050 [J ] . Chin Med J ， 2024 ， 137 （ 21 ）： 2577 - 2582 .

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

JI Y T ， ZHANG Y M ， LIU S W ， et al . The epidemiological landscape of lung cancer：current status，temporal trend and future projections based on the latest estimates from GLOBOCAN 2022 [J ] . J Natl Cancer Cent ， 2025 ， 5 （ 3 ）： 278 - 286 .

SADEGHI M S ， LOTFI M ， SOLTANI N ， et al . Recent advances on high-efficiency of microRNAs in different types of lung cancer：a comprehensive review [J ] . Cancer Cell Int ， 2023 ， 23 （ 1 ）： 284 .

YANG J C ， KIM Y J ， LEE S H ， et al . 4O：amivantamab plus lazertinib vs osimertinib in first-line （1L） EGFR-mutant （EGFRm） advanced NSCLC：final overall survival （OS） from the phase Ⅲ MARIPOSA study [J ] . J Thorac Oncol ， 2025 ， 20 （ 3 ）： S6 - S8 .

YUAN D M ， SONG Y . Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation [J ] . Zhonghua Zhong Liu Za Zhi ， 2017 ， 39 （ 2 ）： 98 - 101 .

SAW S P L ， LE X N ， HENDRIKS L E L ， et al . New treatment options for patients with oncogene-addicted non-small cell lung cancer focusing on EGFR-mutant tumors [J ] . Am Soc Clin Oncol Educ Book ， 2024 ， 44 （ 3 ）： e432516 .

CHO B C ， LU S ， FELIP E ， et al . Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [J ] . N Engl J Med ， 2024 ， 391 （ 16 ）： 1486 - 1498 .

于金明 . 中国临床肿瘤学会（CSCO）常见恶性肿瘤诊疗指南：2025 [M ] . 北京：人民卫生出版社， 2025 ： 98 - 115 .

EISENHAUER E A ， THERASSE P ， BOGAERTS J ， et al . New response evaluation criteria in solid tumours：revised RECIST guideline：version 1.1 [J ] . Eur J Cancer ， 2009 ， 45 （ 2 ）： 228 - 247 .

SPARANO J A ， GRAY R J ， MAKOWER D F ， et al . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [J ] . N Engl J Med ， 2018 ， 379 （ 2 ）： 111 - 121 .

梁淼，刘洋，王宪英 . 埃万妥单抗联合化疗用于EGFR突变的晚期NSCLC的成本-效果分析 [J ] . 中国药房， 2025 ， 36 （ 6 ）： 715 - 720 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 36 - 46 .

WAN X M ， PENG L B ， LI Y J . A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations：a simulation study [J ] . PLoS One ， 2015 ， 10 （ 3 ）： e0121353 .

LIU N ， ZHOU Y H ， LEE J J . IPDfromKM：reconstruct individual patient data from published Kaplan-Meier survival curves [J ] . BMC Med Res Methodol ， 2021 ， 21 （ 1 ）： 111 .

XIANG H ， MENG K H ， WU M Y ， et al . Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China：based on the ASTRUM-004 trial [J ] . Expert Rev Pharmacoecon Outcomes Res ， 2024 ， 24 （ 8 ）： 1043 - 1051 .

齐冉，刘旭婷，高胜男，等 . 劳拉替尼与阿来替尼一线治疗间变性淋巴瘤激酶阳性非小细胞肺癌的药物经济学评价 [J ] . 中国药业， 2023 ， 32 （ 5 ）： 115 - 119 .

苏广全，易仁平，方苹苹，等 . 伏美替尼对比吉非替尼单药一线治疗表皮生长因子受体突变晚期非小细胞肺癌的成本-效果分析 [J ] . 医药导报， 2024 ， 43 （ 8 ）： 1245 - 1251 .

刘佳，贺小宁 . 奥希替尼用于表皮生长因子受体突变阳性非小细胞肺癌辅助治疗的成本-效用分析 [J ] . 世界临床药物， 2022 ， 43 （ 6 ）： 736 - 745 .

WU Q J ， LI Q ， QIN Y . A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer [J ] . Lung Cancer ， 2025 ， 203 ： 108533 .

ZHANG H ， LI Y Y ， LIU Y H ， et al . Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations [J ] . Front Pharmacol ， 2025 ， 16 ： 1527614 .

汤雅倩，赵明烨，唐文熙 . 信迪利单抗对比卡瑞利珠单抗一线治疗晚期非鳞状非小细胞肺癌的经济学评价 [J ] . 卫生经济研究， 2023 ， 40 （ 2 ）： 34 - 40 .

任挺，王琳宁，常峰，等 . 阿美替尼对比奥希替尼二线治疗EGFR T790M阳性的晚期非小细胞肺癌的成本-效用分析 [J ] . 中南药学， 2024 ， 22 （ 12 ）： 3382 - 3387 .

NAFEES B ， LLOYD A J ， DEWILDE S ， et al . Health state utilities in non-small cell lung cancer：an international study [J ] . Asia Pac J Clin Oncol ， 2017 ， 13 （ 5 ）： e195 - e203 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer

Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer

Related Author

WANG Mingxia

JIA Caifeng

HU Dongxue

GAO Han

FENG Rui

SUN Xiaoli

SHAN Bin

LIANG Ping

Related Institution

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University

School of Health Emergency Management， Tianjin University

School of Pharmacy， Hebei Medical University

Dept. of Pharmacy， Hebei Children’s Hospital

⁰

Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC

DOI：10.6039/j.issn.1001-0408.2026.05.14

摘要

Abstract

关键词

Keywords

references